Table 4. Cutoff values of the serum MMP-3 levels at 12 weeks for the US remission and the MMP-3 ratio for the DAS and US remission.
| Cutoff | AUC, % | DAS remission | P | US remission | P | Se, % | Sp, % | PPV, % | NPV, % | PLR | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (+) | (-) | (+) | (-) | ||||||||||
| n = 20 | n = 23 | n = 11 | n = 31 | ||||||||||
| Serum MMP-3 (ng/mL) | ≤76.7 | 77.3 | – | – | – | 8 | 12 | 0.081 | 81.8 | 61.4 | 40 | 86.4 | 2.11 |
| MMP-3 ratio | ≤1.006 | 71.5 | 15 | 8 | 0.014* | – | – | – | 80 | 65.2 | 65.2 | 75 | 2.3 |
| ≤0.864 | 71.3 | – | – | – | 8 | 8 | 0.011* | 72.7 | 74.3 | 50 | 88.5 | 2.82 | |
MMP-3: matrix metalloproteinase 3, MMP-3 ratio: the ratio of the serum matrix metalloproteinase 3 levels at baseline to those at 12 weeks, US: ultrasound, DAS: disease activity score, AUC: area under the curve, Se: sensitivity, Sp: specificity, PPV: positive predictive value, NPV: negative predictive value, PLR: positive likelihood ratio. Receiver operating characteristic curves were generated to determine the optimal cutoff value of the serum MMP-3 levels and the MMP-3 ratio. P-values were estimated using Fisher’s exact test.
*P <0.05.